BRPI0908496A2 - inibição de angiogênese - Google Patents

inibição de angiogênese

Info

Publication number
BRPI0908496A2
BRPI0908496A2 BRPI0908496A BRPI0908496A BRPI0908496A2 BR PI0908496 A2 BRPI0908496 A2 BR PI0908496A2 BR PI0908496 A BRPI0908496 A BR PI0908496A BR PI0908496 A BRPI0908496 A BR PI0908496A BR PI0908496 A2 BRPI0908496 A2 BR PI0908496A2
Authority
BR
Brazil
Prior art keywords
heavy chain
angiogenesis inhibition
vectors encoding
fusion proteins
igg heavy
Prior art date
Application number
BRPI0908496A
Other languages
English (en)
Portuguese (pt)
Inventor
Scaria Abraham
Wadsworth Samuel
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0908496A2 publication Critical patent/BRPI0908496A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0908496A 2008-02-20 2009-02-20 inibição de angiogênese BRPI0908496A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3007208P 2008-02-20 2008-02-20
US3454608P 2008-03-07 2008-03-07
US5663208P 2008-05-28 2008-05-28
PCT/US2009/034709 WO2009105669A2 (en) 2008-02-20 2009-02-20 Angiogenesis inhibition

Publications (1)

Publication Number Publication Date
BRPI0908496A2 true BRPI0908496A2 (pt) 2019-01-15

Family

ID=40986215

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908496A BRPI0908496A2 (pt) 2008-02-20 2009-02-20 inibição de angiogênese

Country Status (5)

Country Link
JP (1) JP2011512417A (ja)
CN (1) CN101951925A (ja)
BR (1) BRPI0908496A2 (ja)
IL (1) IL207641A0 (ja)
WO (1) WO2009105669A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9637534B2 (en) * 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
CN111068072A (zh) * 2014-02-06 2020-04-28 建新公司 用于治疗和预防黄斑变性的组合物及方法
EP3119798B1 (en) 2014-03-17 2020-08-05 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
EA201791939A1 (ru) 2015-03-02 2018-01-31 Адверум Байотекнолоджиз, Инк. Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
RU2712623C2 (ru) 2015-03-31 2020-01-30 Илдонг Фарм. Ко., Лтд. Фармацевтическая композиция для предотвращения и лечения заболеваний глаз, содержащая в качестве активного ингредиента белок слияния, в котором слиты проникающий в ткань пептид и препарат против фактора роста эндотелия сосудов
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
GB201806333D0 (en) * 2018-04-18 2018-05-30 Glaxosmithkline Ip Dev Ltd Parvovirus vector production
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496944B1 (en) * 2002-05-01 2008-08-20 University of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
JP4944032B2 (ja) * 2004-09-13 2012-05-30 ジェンザイム・コーポレーション 多量体構築物

Also Published As

Publication number Publication date
WO2009105669A3 (en) 2009-12-17
CN101951925A (zh) 2011-01-19
JP2011512417A (ja) 2011-04-21
WO2009105669A2 (en) 2009-08-27
IL207641A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
BRPI0908496A2 (pt) inibição de angiogênese
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CO6400232A2 (es) Proteína de enlace al receptores cgrp humano
MA40882B1 (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
MY197854A (en) Antibodies against signal-regulatory protein alpha and methods of use
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CY1120281T1 (el) Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
CR20130126A (es) Anticuerpos anti-ox40 y métodos de uso de los mismos
AR093788A1 (es) Inmunoterapia con agentes de enlace
EA201400488A1 (ru) Полипептидные конструкции и их применение
CL2014000737A1 (es) Proteina de fusion de funcion dual que comprende una region agonista del receptor de glp-1 y una region agonista del receptor de fgf21.
BRPI0915367B8 (pt) peptídeo anti-p2x7
ATE500268T1 (de) Peptide mit neuropeptide-2 rezeptor agonist aktivität
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
TN2014000120A1 (en) Cd27l antigen binding proteins
MX2010004910A (es) Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
DK2197900T3 (da) Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer
EA201491959A1 (ru) Агонистические пептиды для par4

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 61/030,072 , US 61/034,546 E US 61/056,632 REIVINDICADAS NO PCT/US2009/034709, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E ART 2O DA RESOLUCAO INPI 179 DE 21/02/2017. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (GENZYME CORPORATION) SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]